Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Testing Dispatch

Independent analysis puts a WWB exenatide lot at 98.5%, against 96.6% on the certificate

The result is unremarkable. What the report omits is not.

An independent purity determination on exenatide material sold by WWB has returned 98.5%, a figure 1.5 percentage points below the number printed on the accompanying certificate. The analysis was performed by PeptideMeter on a vial the Journal bought as an ordinary retail customer in February 2025 and posted unopened.

The Journal purchased 600 vials from the same lot and had 11 of them analysed separately, in order to distinguish vial-to-vial variation from method variation. Vial-to-vial agreement was within 0.4 percentage points. Method-to-method disagreement was an order of magnitude larger.

Batch variance rather than vendor quality is the recurring finding of this programme. Across the 11 determinations the Journal has commissioned to date, within-vendor spread has been wider than between-vendor spread for two thirds of the companies tracked, which is an argument against rating any supplier on a single number.

"The useful thing in that report is not the percentage, it is the system suitability data," said Yusuf Kandemir, freight and customs broker, Istanbul. "It is the only part that tells you whether the percentage means anything."

WWB’s dossier has been updated with this determination and with the date of the request for comment. The dossier’s "what we could not verify" box records the questions still outstanding.

Related coverage